Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

Tempus AI reports trailing revenue of $1.27B (≈30% annual growth) with a backlog >$1.1B and a trailing net loss of $245M; analysts project ~30% revenue CAGR and consensus price targets implying >60% upside, driven by a data flywheel from diagnostics and licensing. Recursion averages 330 compounds synthesized in 17 months versus the industry 2,500/42 months, posted FY2025 revenue of $74.7M, has >$500M in cumulative partner milestone commitments, received $213M for dataset access from Roche/Genentech and $134M from Sanofi, and reported a 43% median reduction in polyp burden in its first clinical PoC; it is pre-profit but has cash runway into 2028.

Analysis

The real moat here is not individual molecules but asymmetric fixed-cost infrastructure: automated wet labs + curated clinical datasets + production-scale models create winner-take-most economics where marginal cost of new targets collapses and bargaining power shifts toward the platform owner. That concentration will reroute early-stage spend (CRO bookings, sequencing volume, reagent orders) into a small set of suppliers and partners, creating upstream single-source exposures and downstream partner-dependence that amplify both upside and systemic risk.

Risks are highly path-dependent and calendarized: clinical readouts and partner renewals are the primary re-rating events over the next 6–24 months, while regulatory/data-governance developments and compute-price cycles drive structural margin outcomes over multiple years. A binary clinical failure or a major partner churn can erase a large portion of sentiment quickly, while a sequence of positive technical milestones tends to compound valuations non-linearly because the business is priced for long-duration optionality rather than near-term cash flow.

The consensus underestimates two second-order outcomes: 1) commoditization risk if federated clinical datasets and interoperability standards lower entry barriers (reducing exclusivity of proprietary data), and 2) hardware/capex coupling — a spike in GPU prices or supply constraints can meaningfully raise marginal cost-per-inference and slow model-driven throughput. If the data flywheel holds, these platforms will reprice to software-like multiples; if it breaks, downside is rapid and deep.

Key Decisions for Investors

• Long RXRX via a directional call spread (9–15 month tenor). Position size 2–3% of portfolio; target 2–4x on successful mid-stage readouts or partner milestones. Risk: premium loss on binary clinical setbacks; hedge with a small short of high-beta discovery names.
• Long TEM core equity with protective puts (6–12 month). Size 3–5%; objective capture continued data-monetization re-rating (40–80% upside) while limiting downside to ~15–25% by put cost. Monitor quarterly data licensing growth vs. unit test volumes as a trigger for scale-up.
• Pairs trade: long TEM / short SNY (6–18 month, market-neutral sizing). Size each leg to net 1–2% directional exposure; thesis: premium for proprietary clinical flywheels should outcompete legacy R&D spend. Close or rebalance on material partner churn or regulatory clampdowns.
• Tail hedge: buy NVDA 9–12 month calls (small position, 0.5–1%) to insure against compute-capacity squeezes or a broader AI demand spike that re-rates platform multiples. This protects against scenarios where compute scarcity, not biology, becomes the binding constraint.